MAFA
AZN icon

MJT & Associates Financial Advisory’s AstraZeneca AZN Stock Holding History

MJT & Associates Financial Advisory’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.5K Buy
+66
New +$12.4K 0.01% 173
2026
Q1 		– Sell
-81
Closed -$14.8K – 448
2025
Q4 		$14.8K Hold
81
– – 0.01% 147
2025
Q3 		$12.4K Hold
81
– – 0.01% 171
2025
Q2 		$11.3K Hold
81
– – 0.01% 201
2025
Q1 		$11.8K Buy
+81
New +$11.7K 0.01% 197

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

MJT & Associates Financial Advisory's AZN Position: Q2 2026 in Review

MJT & Associates Financial Advisory opened a new position in AstraZeneca (AZN) in Q2 2026: 66 shares worth $12.5K. The stake represents 0.01% of the portfolio and ranks #173 among its holdings. This is a return to the name: MJT & Associates Financial Advisory previously reported a position in AZN as recently as Q4 2025.

MJT & Associates Financial Advisory first reported a position in AZN in Q1 2025 and has held it in 5 quarters since. The position peaked at $14.8K in Q4 2025. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • MJT & Associates Financial Advisory held 66 shares of AstraZeneca worth $12.5K as of Q2 2026.
  • AstraZeneca was a new MJT & Associates Financial Advisory position in Q2 2026.
  • AstraZeneca made up 0.01% of MJT & Associates Financial Advisory's portfolio in Q2 2026, its #173 holding.
  • MJT & Associates Financial Advisory first reported a position in AstraZeneca in Q1 2025 and has held it in 5 quarters since.
  • MJT & Associates Financial Advisory's AstraZeneca position peaked at $14.8K in Q4 2025.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on MJT & Associates Financial Advisory's 13F filing for Q2 2026, filed 6 Jul 2026.